ERNA Spiked 92% on Breakthrough Cancer Data — RTPR Had the Wire in Under 500ms
ERNA spiked 92% on preclinical ovarian cancer results. RTPR delivered the GlobeNewswire release at $4, before the run to $7.70.
Ernexa Therapeutics (NASDAQ: ERNA) spiked 92% on May 6, 2026, after releasing preclinical data for its lead oncology candidate. RTPR subscribers had the wire at $4 — the entry point before the stock ran toward its short-term peak of $7.70.
What the Release Said
The press release announced that ERNA-101, the company's investigational therapy, achieved 100% survival and complete tumor elimination in preclinical ovarian cancer models. Those are the kind of results that get a micro-cap biotech repriced in minutes.
Ovarian cancer is notoriously difficult to treat, and preclinical results showing complete tumor elimination — while still far from human trials — signal strong mechanistic proof-of-concept. The market reacted accordingly.
The Price Action
ERNA was trading at $4 when the GlobeNewswire release crossed. From that entry point, the stock spiked to a short-term peak of $7.70 — a 92% gain for anyone positioned early.
Preclinical catalysts in oncology don't always move stocks this hard, but when the data reads "100% survival" and "complete tumor elimination," traders pay attention. The move was fast and decisive.
Why Speed Mattered
Biotech catalysts are binary. Either the data is good or it isn't. When it's good, the window to act is measured in seconds, not minutes.
At $4, ERNA was still digesting the headline. By the time the stock approached $7.70, the opportunity had already compressed significantly. The difference between seeing the wire first and seeing it on a free aggregator four minutes later was the difference between a $4 entry and chasing a move already well underway.
RTPR Speed: The GlobeNewswire release hit RTPR subscribers in under 500ms at $4. Free aggregators typically lag 2–4 minutes behind the wire. By then, ERNA was already spiking toward $7.70.
The Takeaway
ERNA-101's preclinical results moved the stock nearly double in a single session. For traders watching the wire in real time, the $4 entry was available before the spike began. For everyone else, the news arrived with the move already in progress.
This is how biotech catalysts work. The data drops, the stock reprices, and the fastest traders capture the spread.
Want This Speed?
RTPR delivered this GlobeNewswire release at $4 — before ERNA spiked 92% to $7.70. If you're trading biotech catalysts, milliseconds matter.
Check out RTPR pricing or read the API docs to see how it works.